<!DOCTYPE html>
<html>
	<head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <title>Effient Clinical Trial Landing Page</title>
        <meta name="description" content="" />
        <meta name="keywords" content="" />
        <meta name="viewport" content="width=device-width" />
        <link rel="stylesheet" type="text/css" href="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/css/jquery.mCustomScrollbar.css" />
        <link rel="stylesheet" type="text/css" href="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/css/styles.css" />
        <script>
			var require = {
				deps: ["https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/css_browser_selector.js"],
				callback: function(module1) {
				}
			};
		</script>
        <script data-main="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/js/require.js" src="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/js/require.js"></script>
        <script type="text/javascript" src="http://ajax.googleapis.com/ajax/libs/jquery/1.8.3/jquery.min.js"></script>
        <script type="text/javascript" src="http://www.effient.com/Scripts/jquery.easing.1.3.js"></script>
        <script type="text/javascript" src="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/js/jquery.mCustomScrollbar.concat.min.js"></script>
        <!--[if gte IE 9]>
            <style type="text/css">
                .gradient, button.button {
                   filter: none;
                }
            </style>
        <![endif]-->
        <!-- [if lt IE 9] -->
		<script>
            var elements = ['header', 'nav', 'section', 'article', 'aside', 'footer'];
			for (var i = 0; i < elements.length; i++) {
				document.createElement(elements[i]);
			}
        </script>
        <!-- [endif] -->
        <!--[if IE 8]> 
        	<html class="ie8"> 
        <![endif]-->
        <!--[if lte IE 7]> 
        	<html class="ie7"> 
        <![endif]-->
    </head>
    <body>
    	<div class="header_content_container">
        	<header>
                <div class="header_top">
                    <div class="header_top_left">
                    	<div id="header_links">
                            <a href="http://pi.lilly.com/us/effient.pdf">Prescribing Information</a><br />
                            <a href="http://pi.lilly.com/us/effient-ppi.pdf">Medication Guide</a><br />
                        </div>
                        <div id="logo_header">
                            <a href="http://www.effienthcp.com/Pages/index.aspx"><img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/effient_logo_header.png" width="131" height="52" alt="Effient (prasugrel) tablets" /></a>
                        </div>
                        <div class="clearfix"></div>
                    </div>
                    <div class="isi_header_container">
                        <div class="isi_header_main">
                            <h2>Important Safety Information</h2>
                            <a class="view_more" href="#">View more</a>
                            <div class="clearfix"></div>
                            <div class="bleeding_risk_header">
                                <h3>Warning: Bleeding Risk</h3><br />
                                <p>Effient<sup>&reg;</sup> (prasugrel) can cause significant, sometimes fatal, bleeding.</p>
                                <p>Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.</p>
                                <p>In patients &ge;75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.</p>
                                <p>Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.</p>
                                <p class="addtl_risk">Additional risk factors for bleeding include:</p>
                                <ul>
                                    <li>body weight &lt;60 kg</li>
                                    <li>propensity to bleed</li>
                                    <li>concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs])</li>
                                </ul>
                                <p>Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.</p>
                                <p>If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.</p>
                            </div>
                        </div>
                    </div>
					<div class="clearfix"></div>
                </div>
                <p>Effient<sup>&reg;</sup> (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI. The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.</p>
                <div class="header_tabs">
                	<ul>
                    	<li><a href="#fifteen_months">Efficacy Through<br class="yes_mobile_inline" /> 
                        15 Months</a></li>
                        <li><a href="#seven_days">Efficacy at 7 Days</a></li>
                        <li><a href="#isi_main">Important Safety<br class="yes_mobile_inline" />
                        Information</a></li>
                    </ul>
                </div>
            </header>
        </div>
        <div class="header_banner_wrapper">
            <div class="header_banner_container">
                Compare Effient<sup>&reg;</sup> (prasugrel) and clopidogrel thrombotic<br class="no_mobile" />
				CV event reductions at 2 time frames.
            </div>
        </div>
        <div class="main_content_wrapper">
            <div class="main_content_container">
                <div class="get_samples_cta">
                    <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/green_triangular_bullet_large.png" width="13" height="13" />
                    <span><a href="http://mail.dsicustomerservice.com/p/Daiichi_Sankyo/Effient_Registration">Get samples</a> for your patients.</span>
                </div>
                <!--[if lte IE 8]>
                    <a name="fifteen_months" id="fifteen_months">&nbsp;</a>
                <![endif]-->
                <section class="chart_one">
                    <a name="fifteen_months" id="fifteen_months"></a>
                    <header>
                    	<!--[if lte IE 8]>
                        	<img class="round_corners_top" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_top_1.png" width="980" height="9" />
                        <![endif]-->
                        <h2>Greater reductions in thrombotic CV events for STEMI patients<br class="no_mobile" />
                        through 15 months with Effient plus ASA vs clopidogrel plus ASA</h2>
                    </header>
                    <div class="chart_section_main">
                        <p class="intro">In TRITON-TIMI 38, Effient plus ASA provided greater protection against the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke in the STEMI population managed with PCI compared with clopidogrel plus ASA. These benefits were accompanied by an increased risk of bleeding, including life-threatening and fatal bleeding, compared to clopidogrel.&sup1;</p>
                        <div id="chart_one_cta">
                            <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/green_triangular_bullet_small.png" width="9" height="10" />
                            <span><a href="http://www.effienthcp.com/Pages/clinical-study.aspx">Click here for TRITON-TIMI 38 study design.</a></span>
                        </div>
                        <div class="section_twocol_split">
                            <div class="section_left_col">
                                <div class="primary_composite_chart">
                                    <div class="chart_label">
                                        <h4>Primary composite endpoint: STEMI through 15 months*<sup>1-3</sup></h4>
                                    </div>
                                    <div class="pc_chart_main">
                                        <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/primary_composite_endpoint_chart.png" width="356" height="198" alt="Chart image" />
                                        
                                    </div>
                                </div>
                                <!--[if lte IE 8]>
                                    <img class="round_corners_bottom" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/chart_image_rounded_corners_bottom.png" width="412" height="9" />
                                <![endif]-->
                            </div>
                            <div class="section_right_col">
                                <div class="primary_composite_text">
                                	<p class="small yes_mobile_block">
                                        *Observed rates.<br />
                                        <sup>&dagger;</sup>Absolute risk reduction.<br />
                                        <sup>&Dagger;</sup>Relative risk reduction.
                                    </p>
                                    <ul>
                                        <li>Difference in event rates separated early but did not continue to diverge over time.</li>
                                    </ul><br />
                                    <h4>Important efficacy considerations</h4>
                                    <ul>
                                        <li>Difference in treatments was primarily driven by a significant reduction in nonfatal MIs, with no significant difference in CV death or nonfatal stroke&sup1;</li>
                                        <li class="en_dash">In the overall study population, approximately 40% of MIs occurred periprocedurally and were detected solely by changes in CK-MB</li>
                                    </ul><br />
                                    <h4>Important study design consideration</h4>
                                    <ul>
                                        <li>In TRITON-TIMI 38, the LD of clopidogrel was delayed relative to the placebo-controlled trials that supported its approval for ACS&sup1;</li>
                                    </ul><br class="no_mobile" />
                                    <p class="small no_mobile">
                                        *Observed rates.<br />
                                        <sup>&dagger;</sup>Absolute risk reduction.<br />
                                        <sup>&Dagger;</sup>Relative risk reduction.
                                    </p>
                                </div>
                            </div>
                            <div class="clearfix"></div>
                        </div>
                        <h3>Selected Safety: Bleeding rates in TRITON-TIMI 38</h3>
                        <p class="outro">Effient can cause significant, sometimes fatal, bleeding. Overall rates of non-CABG TIMI major or minor bleeding were significantly higher with Effient plus ASA (4.5%) compared with clopidogrel plus ASA (3.4%). The rates of fatal bleeding were 0.3% with Effient plus ASA and 0.1% with clopidogrel plus ASA. In patients who underwent CABG (N=437), the rates of CABG-related TIMI major or minor bleeding were 14.1% with Effient plus ASA and 4.5% with clopidogrel plus ASA.</p>
                    </div>
                    <!--[if lte IE 8]>
                        <img class="round_corners_bottom" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_bottom_1.png" width="980" height="9" />
                    <![endif]-->
                </section>
                <section class="video_wrapper">
                    <div class="back_to_top"><a href="#">Back to Top</a></div>
                    <div class="video_text_container">
                    	<!--[if lte IE 8]>
                        	<img class="round_corners_top_2" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_top_2.png" width="980" height="9" />
                        <![endif]-->
                        <div class="video_text">
                            <h2>Get an up-close look at the STEMI cohort of the<br class="no_mobile" />
                            TRITON-TIMI 38 trial.</h2><br />
                            <p>Dr. Richard Gilmore examines the significance of Effient for STEMI patients.</p>
                        </div>
                        <div class="video_container">
                        	<!--[if lte IE 8]>
                                <img class="round_corners_top_3" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/video_rounded_corners_top.png" width="285" height="9" />
                            <![endif]-->
                            <!-- Start of Brightcove Player -->
                            <div style="display:none"></div>
                            <!-- By use of this code snippet, I agree to the Brightcove Publisher T and C 
                            found at https://accounts.brightcove.com/en/terms-and-conditions/. -->
                            <script language="JavaScript" type="text/javascript" src="http://admin.brightcove.com/js/BrightcoveExperiences.js"></script>
                            <object id="myExperience2607782594001" class="BrightcoveExperience">
                                <param name="bgcolor" value="#FFFFFF" />
                                <param name="playerID" value="2715860296001" />
                                <param name="playerKey" value="AQ~~,AAAA8_MTmek~,KrGepHw1JOSnTAmojKs8uwOFMQd5WqJb" />
                                <param name="isVid" value="true" />
                                <param name="isUI" value="true" />
                                <param name="dynamicStreaming" value="true" />
                                <param name="@videoPlayer" value="2607782594001" />
                            </object>
                            <!-- This script tag will cause the Brightcove Players defined above it to be created as soon
                            as the line is read by the browser. If you wish to have the player instantiated only after
                            the rest of the HTML is processed and the page load is complete, remove the line. -->
                            <script type="text/javascript">brightcove.createExperiences();</script>
                            <!-- End of Brightcove Player -->
                            <!--[if lte IE 8]>
                                <img class="round_corners_bottom_3" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/video_rounded_corners_bottom.png" width="285" height="9" />
                            <![endif]-->
                        </div>
                        <div class="clearfix"></div>
                    </div>
                    <!--[if lte IE 8]>
                        <img class="round_corners_bottom_2" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_bottom_2.png" width="980" height="9" />
                    <![endif]-->
                </section>
                <div class="back_to_top"><a href="#">Back to Top</a></div>
                <!--[if lte IE 8]>
                    <a name="seven_days" id="seven_days">&nbsp;</a>
                <![endif]-->
                <section class="chart_two">
                    <a name="seven_days" id="seven_days"></a>
                    <header>
                    	<!--[if lte IE 8]>
                        	<img class="round_corners_top" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_top_1.png" width="980" height="9" />
                        <![endif]-->
                        <h2>Reductions in thrombotic CV events for STEMI-PCI patients<br class="no_mobile" />
                        within hours with Effient plus ASA vs clopidogrel plus ASA</h2>
                    </header>
                    <div class="chart_section_main">
                        <p class="intro">In TRITON-TIMI 38, Effient plus ASA demonstrated continuous risk reduction in the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke from days 0-7 compared with clopidogrel plus ASA in the STEMI population.<sup>1,4</sup></p>
                        <div class="section_twocol_split">
                            <div class="section_left_col">
                                <div class="observed_risk_chart">
                                    <div class="chart_label">
                                        <h4>Observed Risk Reduction in STEMI-PCI Patients through 7 days*<sup>1,4</sup></h4>
                                    </div>
                                    <div class="or_chart_main">
                                        <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/observed_risk_reduction_chart.png" width="386" height="225" alt="Chart image" /><br />
                                    </div>
                                </div>
                                <!--[if lte IE 8]>
                                    <img class="round_corners_bottom" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/chart_image_rounded_corners_bottom.png" width="412" height="9" />
                                <![endif]-->
                            </div>
                            <div class="section_right_col">
                                <div class="observed_risk_text">
                                	<p class="small yes_mobile_block">
                                        *The curves separated within the first few hours. This early separation was maintained throughout the 15-month follow-up, but there was no progressive divergence after the first few weeks.<br />
                                        <sup>&dagger;</sup>Absolute risk reduction.<br />
                                        <sup>&Dagger;</sup>ARR is calculated from observed data, not Kaplan-Meier (KM) rates.<br />
                                        <sup>&sect;</sup>Relative risk reduction.
                                    </p>
                                    <ul>
                                        <li>From days 0–7, observed rates of the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke in the STEMI population at 7 days for Effient plus ASA and clopidogrel plus ASA were 5.5% vs 7.8%, respectively (2.3% ARR; <em>P</em>=0.008)&sup1;</li>
                                    </ul><br />
                                    <h4>Important efficacy considerations</h4>
                                    <ul>
                                        <li>Difference in treatments was primarily driven by a significant reduction in nonfatal MIs, with no significant difference in CV death or nonfatal stroke&sup1;</li>
                                        <li class="en_dash">In the overall study population, approximately 40% of MIs occurred periprocedurally and were detected solely by changes in CK-MB</li>
                                    </ul><br />
                                    <h4>Important study design consideration</h4>
                                    <ul>
                                        <li>In TRITON-TIMI 38, the LD of clopidogrel was delayed relative to the placebo-controlled trials that supported its approval for ACS&sup1;</li>
                                    </ul><br />
                                    <p class="small no_mobile">
                                        *The curves separated within the first few hours. This early separation was maintained throughout the 15-month follow-up, but there was no progressive divergence after the first few weeks.<br />
                                        <sup>&dagger;</sup>Absolute risk reduction.<br />
                                        <sup>&Dagger;</sup>ARR is calculated from observed data, not Kaplan-Meier (KM) rates.<br />
                                        <sup>&sect;</sup>Relative risk reduction.
                                    </p>
                                </div>
                            </div>
                            <div class="clearfix"></div>
                        </div>
                        <h3>Selected Safety: Bleeding rates in TRITON-TIMI 38</h3>
                        <p class="outro">Effient can cause significant, sometimes fatal, bleeding. Overall rates of non-CABG TIMI major or minor bleeding were significantly higher with Effient plus ASA (4.5%) compared with clopidogrel plus ASA (3.4%). The rates of fatal bleeding were 0.3% with Effient plus ASA and 0.1% with clopidogrel plus ASA. In patients who underwent CABG (N=437), the rates of CABG-related TIMI major or minor bleeding were 14.1% with Effient plus ASA and 4.5% with clopidogrel plus ASA.</p>
                    </div>
                    <!--[if lte IE 8]>
                        <img class="round_corners_bottom" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_bottom_1.png" width="980" height="9" />
                    <![endif]-->
                </section>
                <div class="back_to_top"><a href="#">Back to Top</a></div>
                <section class="free_sample">
                    <header>
                    	<!--[if lte IE 8]>
                        	<img class="round_corners_top" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_top_1.png" width="980" height="9" />
                        <![endif]-->
                        <h2>Start your patients with a free sample.</h2>
                    </header>
                    <div class="sample_section_main">
                        <p class="intro no_mobile">Effient offers convenient, one-tablet, once-daily maintenance dosing.</p>
                        <div class="section_twocol_split">
                            <div class="section_left_col">
                            	<p class="yes_mobile_block">Effient offers convenient, one-tablet, once-daily maintenance dosing.</p>
                                <form action="http://mail.dsicustomerservice.com/p/Daiichi_Sankyo/Effient_Registration" method="get">
                                    <button class="button">
                                        <span class="button_text">Get samples</span>
                                        <span class="button_right"><img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/cta_btn_triangle.png" width="8" height="19" /></span>
                                    </button>
                                </form>
                                <!--[if lte IE 8]>
                                    <a href="http://mail.dsicustomerservice.com/p/Daiichi_Sankyo/Effient_Registration"><img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/get_samples_btn.png" width="171" height="42" /></a>
                                <![endif]-->
                            </div>
                            <div class="section_right_col">
                                <img class="no_mobile" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/pills_pills_pills.png" width="388" height="122" alt="Effient pills" />
                                <img class="yes_mobile_inline" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/pills_pills_pills_mobile.png" width="238" alt="Effient pills" height="97" />
                            </div>
                            <div class="clearfix"></div>
                        </div>
                    </div>
                    <!--[if lte IE 8]>
                        <img class="round_corners_bottom" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_bottom_1.png" width="980" height="9" />
                    <![endif]-->
                </section>
                <div class="back_to_top"><a href="#">Back to Top</a></div>
                <section class="sss_wrapper">
                    <header>
                    	<!--[if lte IE 8]>
                        	<img class="round_corners_top_2" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_top_2.png" />
                        <![endif]-->
                        <h2>Give the support ACS-PCI patients need to start and stay on Effient as prescribed.</h2>
                    </header>
                    <div class="sss_section_main">
                        <div class="section_threecol_split">
                            <div class="section_left_middle_col">
                                <div class="start">
                                    <div class="sss_headers">
                                    	<!--[if lte IE 8]>
                                            <img class="round_corners_top_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_top.png" width="299" height="9" />
                                        <![endif]-->
                                        <h2>Start</h2>
                                    </div>
                                    <div class="start_main">
                                        <span class="left"><strong>Free 30-day</strong><br />
                                        prescription voucher for patients to start their Effient therapy.</span>
                                        <img class="right" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/free_30_day_trial_offer.jpg" width="133" height="80" alt="Free 30-Day Trial Offer" />
                                        <div class="clearfix"></div>
                                        <p><strong>Stent care kit</strong><br />
                                        Helps educate your patients about their new stent and the role of Effient.</p>
                                    </div>
                                    <!--[if lte IE 8]>
                                        <img class="round_corners_bottom_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_bottom.png" width="299" height="9" />
                                    <![endif]-->
                                </div>
                                <div class="support">
                                    <div class="sss_headers">
                                    	<!--[if lte IE 8]>
                                            <img class="round_corners_top_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_top.png" width="299" height="9" />
                                        <![endif]-->
                                        <h2>Support</h2>
                                    </div>
                                    <div class="support_main">
                                        <div class="left">
                                            <span>Es<strong>stent</strong>ial Habits<sup>&reg;</sup> gives patients and their families ongoing support.</span><br />
                                            <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/esstential_habits_logo.png" width="105" height="41" alt="Esstential Habits" />
                                        </div>
                                        <img class="right" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/esstential_materials.jpg" width="149" height="134" alt="Esstential support materials" />
                                        <div class="clearfix"></div>
                                    </div>
                                    <!--[if lte IE 8]>
                                        <img class="round_corners_bottom_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_bottom.png" width="299" height="9" />
                                    <![endif]-->
                                </div>
                            </div>
                            <div class="section_right_col">
                                <div class="stay">
                                    <div class="sss_headers">
                                    	<!--[if lte IE 8]>
                                            <img class="round_corners_top_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_top.png" width="299" height="9" />
                                        <![endif]-->
                                        <h2>Stay</h2>
                                    </div>
                                    <div class="start_main">
                                        <span class="left"><strong>Co-pay assistance</strong> to reduce out-of-pocket costs for your patients taking Effient.</span>
                                        <img class="right" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/co-pay_card.jpg" width="133" height="81" alt="Co-Pay Card" />
                                        <div class="clearfix"></div>
                                        <p><strong>Effient.com</strong><br />
                                        Helps patients stay informed about ACS and provides heart-healthy lifestyle tips.</p>
                                    </div>
                                    <!--[if lte IE 8]>
                                        <img class="round_corners_bottom_4" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/sss_round_corners_bottom.png" width="299" height="9" />
                                    <![endif]-->
                                </div>
                                <div class="clearfix"></div>
                            </div>
                            <div class="clearfix"></div>
                        </div>
                        <form action="http://mail.dsicustomerservice.com/p/Daiichi_Sankyo/Effient_Registration" method="get">
                            <button class="button">
                                <span class="button_text">Get patient resources</span>
                                <span class="button_right"><img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/cta_btn_triangle.png" width="8" height="19" /></span>
                            </button>
                        </form>
                        <!--[if lte IE 8]>
                            <a href="http://mail.dsicustomerservice.com/p/Daiichi_Sankyo/Effient_Registration"><img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/get_pat_resources_btn.png" width="240" height="42" /></a>
                        <![endif]-->
                    </div>
                    <!--[if lte IE 8]>
                        <img class="round_corners_bottom_2" src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/rounded_corners_bottom_2.png" />
                    <![endif]-->
                </section>
                <div class="back_to_top"><a href="#">Back to Top</a></div>
                <!--[if lte IE 8]>
                    <a name="isi_main" id="isi_main">&nbsp;</a>
                <![endif]-->
                <section class="isi_main">
                    <a name="isi_main" id="isi_main"></a>
                  <h4 class="isi_heading">IMPORTANT SAFETY INFORMATION</h4>
                    <div class="bleeding_risk_wrapper">
                        <div class="bleeding_risk_main">
                            <h4>WARNING: BLEEDING RISK</h4>
                            <p>Effient<sup>&reg;</sup> (prasugrel) can cause significant, sometimes fatal, bleeding.</p>
                            <p>Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.</p>
                            <p>In patients &ge;75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.</p>
                            <p>Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.</p>
                            <p class="addtl_risk">Additional risk factors for bleeding include:</p>
                            <ul>
                                <li>body weight &lt;60 kg</li>
                                <li>propensity to bleed</li>
                                <li>concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs])</li>
                            </ul>
                            <p>Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.</p>
                            <p>If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.</p>
                        </div>
                    </div>
                    <h4>CONTRAINDICATIONS</h4>
                    <ul>
                        <li>Effient is contraindicated in patients with active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage (ICH), or a history of transient ischemic attack (TIA) or stroke, and in patients with hypersensitivity to prasugrel or any component of the product</li>
                    </ul><br />
                    <h4>WARNINGS AND PRECAUTIONS</h4>
                    <ul>
                        <li>Patients who experience a stroke or TIA while on Effient generally should have therapy discontinued. Effient should also be discontinued for active bleeding and elective surgery</li>
                        <li>Premature discontinuation of Effient increases risk of stent thrombosis, MI, and death</li>
                        <li>Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition that can be fatal, has been reported with Effient, sometimes after a brief exposure (&lt;2 weeks), and requires urgent treatment, including plasmapheresis</li>
                        <li>Hypersensitivity, including angioedema, has been reported in patients receiving Effient, including patients with a history of hypersensitivity reaction to other thienopyridines</li>
                    </ul><br />
                    <h4>ADVERSE REACTIONS</h4>
                    <ul>
                        <li>Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction</li>
                    </ul><br />
                    <p><strong>Please see <a href="http://pi.lilly.com/us/effient.pdf">Prescribing Information</a>, including Boxed Warning regarding bleeding risk, and <a href="http://pi.lilly.com/us/effient-ppi.pdf">Medication Guide</a>.</strong></p>
                    <p><strong>References: 1.</strong> Effient<sup>&reg;</sup> (prasugrel) prescribing information. Daiichi Sankyo, Inc. and Eli Lilly and Company. <strong>2.</strong> Data on file: #EFF20091204a:DSI/Lilly. <strong>3.</strong> Data on file: #EFF20080929c: DSI/Lilly. <strong>4.</strong> Data on file: #EFF20130920a:DSI/Lilly.</p>
                </section>
            </div>
        </div>    
        <footer>
        	<div class="footer_container">
                <div class="footer_main">
                    <ul class="footer_links">
                        <li class="first"><a href="http://www.effienthcp.com/Pages/contactus.aspx">Contact Us</a></li>
                        <li><a href="https://www.lillyhub.com/legal/hcp/daiichisankyo-lilly/privacy.html">Privacy Statement</a></li>
                        <li><a href="https://www.lillyhub.com/legal/hcp/daiichisankyo-lilly/termsofuse.html">Terms of Use</a></li>
                        <li><a href="https://www.lillyhub.com/legal/hcp/daiichisankyo-lilly/copyright.html">Copyright</a></li>
                        <li class="last"><a href="http://www.effienthcp.com/Pages/about-partnership.aspx">About the Partnership</a></li>
                    </ul>
                    <p><sup>&reg;</sup>Effient, Es<strong>stent</strong>ial Habits, and the Effient logo are registered trademarks of Eli Lilly and Company.</p>
                    <p>This site is intended for U.S. Healthcare Professionals Only.</p>
                    <p>Copyright © 2013 Daiichi Sankyo, Inc. and Lilly USA, LLC.<br />
                    All Rights Reserved.  PG87718.   PGHCPISI03October2011.  October 2013.</p>
                    <img src="http://images.bfi0.com/creative/2013/daiichi_sankyo/11/DSIM-A019/effient_touch_3/lp/images/ds_lilly_logo.png" width="92" height="39" alt="Daiichi Sankyo | Lilly" />
                </div>
        	</div>
        </footer>
        <script>
			(function($){
				$(window).load(function(){
					$(".isi_header_container").mCustomScrollbar({
						scrollButtons:{
							enable: true,
						}
					});
				});
			})(jQuery);
			
			$(document).ready(function() {
				$('.view_more').unbind('click');
				$('.view_more').bind('click', function(e){
					e.preventDefault();
					var newDiv = '<div class="isi_header_clone"><a class="close_clone" href="javascript:void(0);">Collapse</a></div>';
					var isiClone = $('.isi_header_container .isi_header_main').clone(true);
					
					$('.header_content_container .header_top').append(newDiv);
					$('.header_content_container .header_top .isi_header_clone').append(isiClone);
					var expandHeight = parseInt($('.isi_header_clone .isi_header_main').outerHeight());
					$('.header_content_container .header_top .isi_header_clone').animate({height: expandHeight + 'px'}, 500)
				});
				$(document).on('click', '.close_clone', function(e){
					e.preventDefault();
					$('.isi_header_clone').animate({height: '20px'}, 500, function(){
						$(this).hide().remove();
					});
				});
			});
		</script>
        <script src="https://cescode.epsilon.com/DSEML_DSI_code/prod/CREATIVE/js/v18a_EffientHCP_PROD_gaTrack.js"></script>
    </body>
</html>